YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The IPO market has made an impressive comeback this year. Momentum began building in the first quarter and accelerated in the second, with traditional IPOs raising $114.1 billion through June 30, 2026 – roughly seven times the amount raise…
[NETFLIX corporate office building with signage on top, located at 1341 Vine Street, Los Angeles] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events t…
Kardigan (KARD) didn't just raise $400 million. The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is not a simple optimism. It's prejudiced. Biotech businesses might tos…
[IPO Concept with Stock Market Graphs] What are the most attractive upcoming initial public offerings in the wake of SpaceX's (SPCX [https://seekingalpha.com/symbol/SPCX]) spectacular market debut? Seeking Alpha analysts Donovan Jones [htt…
Investing.com -- Kardigan Inc. shares rose iver 27% roughly one hour into its Nasdaq debut on Thursday, after the heart-health focused biotech raised $400 million in an initial public offering. The company's shares opened at $16.25 each as…
[IPO Initial Public Offering 3D Graph Chart Background] filo/E+ via Getty Images Kardigan (KARD [https://seekingalpha.com/symbol/KARD]), a clinical-stage precision therapeutics company specializing in unaddressed cardiovascular diseases, h…
Kardigan filed for a U.S. initial public offering targeting a valuation of up to $1.4 billion, the Princeton, New Jersey-based clinical-stage biotech said on Thursday. Its offering consists of 23.3 million shares in a $14-to-$16 price rang…
Just under a year and a half after its debut, Kardigan is eyeing a listing on the Nasdaq to support the continued development of its in-licensed cardiology pipeline – adding another name to the burgeoning list of American biotechs undertak…